ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Up 1.8% – Time to Buy?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)’s stock price traded up 1.8% on Thursday . The company traded as high as $53.88 and last traded at $53.80. 19,145 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 36,471 shares. The stock had previously closed at $52.83.

ALPS Medical Breakthroughs ETF Price Performance

The business’s fifty day moving average price is $53.12 and its two-hundred day moving average price is $51.14.

Institutional Trading of ALPS Medical Breakthroughs ETF

A number of institutional investors have recently bought and sold shares of SBIO. Steward Partners Investment Advisory LLC acquired a new stake in ALPS Medical Breakthroughs ETF in the 4th quarter worth approximately $26,000. Comerica Bank acquired a new stake in ALPS Medical Breakthroughs ETF in the 3rd quarter worth approximately $27,000. Global Retirement Partners LLC acquired a new stake in ALPS Medical Breakthroughs ETF in the 4th quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new stake in ALPS Medical Breakthroughs ETF in the 2nd quarter worth approximately $82,000. Finally, Janney Montgomery Scott LLC acquired a new stake in ALPS Medical Breakthroughs ETF in the 4th quarter worth approximately $220,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.